In a regulatory filing, Lpath (LPTN) also announced that it has retained Agility Clinical to serve as its primary contract research organization, CRO, for the remainder of the Nexus Trial. Lpath initially engaged Agility during the first quarter of 2013 to conduct certain database-management functions in support of the Nexus Trial. Lpath has notified its former primary CRO of its decision to terminate the existing services contract. Lpath believes the change in primary CRO will not change the timing for completion of the clinical trial and will not have a significant impact on the clinical trial costs. Lpath’s corporate partner, Pfizer (PFE) has consented to the change in primary CRO.